Evidence map›Paper›PMID 35912241›Full record

ArticleFrontiers in oncology2022

TOP2A correlates with poor prognosis and affects radioresistance of medulloblastoma.

Yufeng Zhang, Haiyan Yang, Liwen Wang, Huandi Zhou, Ge Zhang, Zhiqing Xiao, Xiaoying Xue

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yufeng ZhangDepartment of Radiotherapy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Haiyan YangDepartment of Pathology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Liwen WangDepartment of Radiotherapy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Huandi ZhouDepartment of Radiotherapy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Ge ZhangDepartment of Radiotherapy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Zhiqing XiaoDepartment of Radiotherapy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Xiaoying XueDepartment of Radiotherapy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Second Hospital of Hebei Medical University · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy remains the standard treatment for medulloblastoma (MB), and the radioresistance contributes to tumor recurrence and poor clinical outcomes. Nuclear DNA topoisomerase II-alpha (TOP2A) is a key catalytic enzyme that initiates DNA replication, and studies have shown that TOP2A is closely related to the therapeutic effects of radiation. In this study, we found that TOP2A was significantly upregulated in MB, and high expression of TOP2A related to poor prognosis of MB patients. Knockdown of TOP2A inhibited MB cell proliferation, migration, and invasion, whereas overexpression of TOP2A enhanced the proliferative and invasive ability of MB cells. Moreover, si-TOP2A transfection in combination with irradiation (IR) significantly reduced the tumorigenicity of MB cells, compared with those transfected with si-TOP2A alone. Cell survival curve analysis revealed that the survival fraction of MB cells was significantly reduced upon TOP2A downregulation and that si-TOP2A-transfected cells had decreased D

Indexed as

medulloblastomaprognosisradioresistanceTOP2AWnt/β-catenin pathway

Identifiers

PMID35912241
PMCPMC9337862
OpenAlexW4285593007

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.